Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
The Drug-Drug Interaction of SHR4640 and Febuxostat in Patients With Hyperuricemia
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT04157959
- Locations
- 🇨🇳
The Affiliated Hospital of QingDao University, Qingdao, Shan Dong, China
A Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in Adults
Phase 2
Suspended
- Conditions
- Interventions
- First Posted Date
- 2019-10-09
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT04121143
- Locations
- 🇨🇳
Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai, Shanghai, China
A Study of HR071603(Ketamine Nasal Spray) in Healthy Subjects
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04108234
- Locations
- 🇨🇳
Beijing AnDing hospital affiliated to Capital Medical University, Beijing, Beijing, China
A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPC
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT04108247
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04108676
- Locations
- 🇨🇳
The third xiangya hospital Hospital,of central south university, Changsha, Hunan, China
A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2020-05-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT04102124
- Locations
- 🇨🇳
Ye Dingwei, Shanghai, China
A Study of SHR4010 in Patients With Hemodialysis
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT04099927
- Locations
- 🇨🇳
Zhongda Hospital Affiliated to Southeast University, Nanjing, Jiangsu, China
A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2022-06-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 594
- Registration Number
- NCT04052932
- Locations
- 🇨🇳
RenJi Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients
Phase 1
Completed
- Conditions
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 23
- Registration Number
- NCT04041011
- Locations
- 🇨🇳
Cancer Hospital of the University of Chinese Academy of Sciences Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Study of SHR-1501 in Patients With Advanced Tumors
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT04025957
- Locations
- 🇨🇳
Cancer hospital, Chinese academy of medical sciences, Beijing, China
© Copyright 2024. All Rights Reserved by MedPath